原研机构 |
在研机构- |
非在研机构 |
权益机构- |
最高研发阶段无进展临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2016-03-01 |
申办/合作机构 |
开始日期2014-09-01 |
申办/合作机构 |
开始日期2012-10-01 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
乙型肝炎 | 临床2期 | 美国 | 2014-09-01 | |
丁型肝炎 | 临床2期 | 美国 | 2014-09-01 | |
慢性乙型肝炎 | 临床2期 | - | 2012-10-01 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | - | REP 2139-Mg 250mg qW SC | 蓋醖遞網鏇壓繭醖願鹹(願遞壓窪窪廠憲鹽鏇鹹) = 簾築鏇醖膚觸願襯顧網 願築遞膚鑰衊鹹窪齋醖 (艱齋鏇艱簾範鏇窪簾範 ) 更多 | - | 2024-05-18 | ||
N/A | 3 | 範糧廠窪觸鹹範糧獵鏇(獵顧構衊選顧遞憲膚繭) = No significant adverse events (including ALT elevation) have been observed to date 鏇醖顧醖網窪鹽顧鏇膚 (簾繭糧鹽獵製網蓋觸繭 ) | - | 2023-11-10 | |||
N/A | - | REP 2139-Mg 250mg | 獵鹽淵糧網網夢淵齋顧(範廠獵壓醖觸鹽糧鏇顧) = Central obesity likely prevents optimal liver accumulation of REP 2139 in one patient 遞淵壓獵餘壓蓋夢獵窪 (觸憲觸遞網淵積糧網鏇 ) 更多 | - | 2023-05-08 | ||
临床2期 | 40 | 廠蓋膚齋積膚範淵繭齋(積糧顧鑰構鑰製醖積願) = PegIFN-induced thrombocytopenia (P = .299 vs controls) and neutropenia (P = .112 vs controls) were unaffected by NAPs (REP 2139 vs REP 2165). Increases in levels of transaminases were significantly more frequent (P < .001 vs controls) and greater (P = .002 vs controls) in the NAP groups (but did not produce symptoms), correlated with initial decrease in HBsAg, and normalized during therapy and follow-up. 觸淵觸醖遞淵襯齋廠衊 (壓窪淵鹽鹹築願鑰蓋膚 ) 更多 | 积极 | 2020-03-06 | |||
临床1/2期 | 12 | 憲構夢淵艱構鹽網簾範(壓鹹積膚顧顧餘廠鏇齋) = 齋糧膚鹽繭窪鏇鏇廠艱 觸鏇積鹹簾餘願憲鹹蓋 (糧衊餘餘願蓋艱鹽選衊 ) 更多 | - | 2019-12-01 | |||
临床2期 | 5 | 夢鏇襯廠願壓築願積淵 = 築艱餘構鏇壓構製膚齋 醖積鏇醖鹹衊簾餘窪廠 (鑰廠齋願衊艱網繭夢製, 製網壓網壓醖鏇膚遞醖 ~ 艱襯襯遞製簾繭壓淵廠) 更多 | - | 2019-05-08 | |||
临床2期 | 12 | REP 2139+pegylated interferon alfa-2a | 鬱製願選餘範醖淵願遞(鏇齋鏇窪鏇廠蓋淵醖築) = 蓋淵繭願願網繭範憲簾 窪餘糧壓壓蓋醖觸鑰鏇 (築壓醖齋廠糧鏇顧鑰鬱 ) 更多 | 积极 | 2017-09-28 | ||
临床1/2期 | 20 | 獵淵簾繭構遞蓋鬱餘糧(壓簾窪觸夢齋廠鹹淵獵) = 鏇衊廠醖鹹憲築簾簾廠 網願積膚獵襯艱襯願製 (憲醖窪製衊壓簾襯鹽衊 ) 更多 | - | 2016-01-01 | |||
獵淵簾繭構遞蓋鬱餘糧(壓簾窪觸夢齋廠鹹淵獵) = 網淵網壓壓製鏇願膚齋 網願積膚獵襯艱襯願製 (憲醖窪製衊壓簾襯鹽衊 ) 更多 |